Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2025)

Historic EBT Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 15.02%.

  • Kiniksa Pharmaceuticals International's EBT Margin rose 214300.0% to 15.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.13%, marking a year-over-year increase of 318800.0%. This contributed to the annual value of 8.54% for FY2024, which is 251800.0% up from last year.
  • Kiniksa Pharmaceuticals International's EBT Margin amounted to 15.02% in Q3 2025, which was up 214300.0% from 14.59% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EBT Margin registered a high of 47.14% during Q3 2022, and its lowest value of 526.34% during Q2 2021.
  • Its 5-year average for EBT Margin is 71.48%, with a median of 15.87% in 2024.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's EBT Margin skyrocketed by 4549100bps in 2022, and later plummeted by -598200bps in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBT Margin (Quarter) stood at 233.66% in 2021, then skyrocketed by 74bps to 61.3% in 2022, then plummeted by -41bps to 86.37% in 2023, then soared by 84bps to 13.86% in 2024, then surged by 208bps to 15.02% in 2025.
  • Its EBT Margin was 15.02% in Q3 2025, compared to 14.59% in Q2 2025 and 11.3% in Q1 2025.